Caplacizumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Caplacizumab and local guidelines before prescribing.

Anti-vWF agent

Mechanism

Anti-von Willebrand factor nanobody.

Uses

Acquired thrombotic thrombocytopenic purpura.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Bleeding, epistaxis, headache.

Interactions

Anticoagulants and antiplatelets increase bleeding.

Contraindications and cautions

Active bleeding

Monitoring

Platelets, bleeding, ADAMTS13

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive; vWF concentrate

Special advice

Use with plasma exchange and immunosuppression; stop 7 days after last plasma exchange.

More from the textbook: uses, cautions and other points
Where it is discussed in the book